"coenzyme Q10 and L carnitine in Benign prismatic hyperplasia"

Effect of combination therapy of coenzyme Q10 and L carnitine and finasteride on treatment management in patients with lower urinary tract symptoms ( LUTS) due to benign prismatic hyperplasia (BPH)

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200623047893N1

Enrollment

Registered

2020-07-26

Start date

2020-06-25

Completion date

Unknown

Last updated

2020-08-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Benign prostatic hyperplasia. Condition 2: Lower urinary tract symptoms.

Interventions

Intervention 1: Intervention group: finasteraid, coenzyme Q10 100 mg , L carnitine 1000mg ,1tablet daily for 8 weeks. Intervention 2: Control group: finasteraid, plasebo ,1tablet daily for 8 weeks.

Eligibility

Sex/Gender

Male

Age

50 Years to 75 Years

Inclusion criteria

Inclusion criteria: 50-75 years old IPSS=8-19 Prostate volume 40-60 cc

Exclusion criteria

Exclusion criteria: urinary tract infections severe liver disease diabetes recent treatment with 5 alpha reductase recent treatment with phototherapy treatment with antiandrogens and antidepressants neurological bladder bladder cancer prostate cancer Take atorvastatin blood pressure

Design outcomes

Primary

Measure	Time frame
Changes in prostate volume. Timepoint: The beginning the study and the end of study. Method of measurement: Sonography.	—

Secondary

Measure	Time frame
IIEF. Timepoint: The beginning and the end of study. Method of measurement: Questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMahsa norouzi

Shiraz University of Medical Sciences

mahsanorouzi89@gmail.com+98 71 3822 9875

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026